Clinical trial
Capecitabine, Docetaxel and Gemcitabine in Patients With Advanced Pancreas…
NCT00320749 · Tony Bekaii-Saab, Other · Completed
Key facts
| NCT number | NCT00320749 |
|---|---|
| Title | Capecitabine, Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer |
| Official title | A Dose Escalating (Phase I) Study Looking at the Biomodulation of Capecitabine by Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer |
| Lead sponsor | Tony Bekaii-Saab, Other |
| Collaborators | University of Michigan Rogel Cancer Center |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | Capecitabine, Docetaxel, Gemcitabine |
| Enrollment | 21 |
| Start date | Dec 1, 2005 |
| Primary completion | Oct 1, 2008 |
| Completion | Jan 1, 2011 |
| First posted | May 3, 2006 |
| Last update posted | Jun 27, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: